EPS for Parex Resources Inc. (PXT) Expected At $0.48; Eagle Pharmaceuticals (EGRX) SI Decreased By 4.41%

April 17, 2018 - By Peter Erickson

Eagle Pharmaceuticals Inc (NASDAQ:EGRX) had a decrease of 4.41% in short interest. EGRX’s SI was 3.19 million shares in April as released by FINRA. Its down 4.41% from 3.34M shares previously. With 212,400 avg volume, 15 days are for Eagle Pharmaceuticals Inc (NASDAQ:EGRX)’s short sellers to cover EGRX’s short positions. The SI to Eagle Pharmaceuticals Inc’s float is 28.25%. The stock increased 0.90% or $0.48 during the last trading session, reaching $54.04. About 91,111 shares traded. Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) has declined 36.05% since April 17, 2017 and is downtrending. It has underperformed by 47.60% the S&P500.

Analysts expect Parex Resources Inc. (TSE:PXT) to report $0.48 EPS on May, 9.They anticipate $0.14 EPS change or 41.18% from last quarter’s $0.34 EPS. T_PXT’s profit would be $74.72M giving it 10.40 P/E if the $0.48 EPS is correct. After having $0.44 EPS previously, Parex Resources Inc.’s analysts see 9.09% EPS growth. The stock increased 0.81% or $0.16 during the last trading session, reaching $19.96. About 242,361 shares traded. Parex Resources Inc. (TSE:PXT) has 0.00% since April 17, 2017 and is . It has underperformed by 11.55% the S&P500.

Parex Resources Inc. engages in the exploration, development, production, and marketing of oil and natural gas in South America. The company has market cap of $3.11 billion. It holds interests in onshore exploration and production blocks totaling approximately 2,091,404 gross acres in Colombia. It has a 20.16 P/E ratio. The firm has proved plus probable reserves of 41.1 million barrels of oil equivalent.

Among 7 analysts covering Parex Resources Inc. (TSE:PXT), 7 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Parex Resources Inc. had 38 analyst reports since August 5, 2015 according to SRatingsIntel. The firm earned “Buy” rating on Wednesday, January 25 by TD Securities. Scotia Capital maintained the shares of PXT in report on Friday, September 29 with “Focus Stock” rating. The rating was maintained by Scotia Capital on Wednesday, March 8 with “Focus Stock”. The firm earned “Outperform” rating on Friday, September 9 by FirstEnergy Capital. Paradigm Research maintained the stock with “Buy” rating in Tuesday, August 25 report. The stock has “Buy” rating by Canaccord Genuity on Thursday, March 2. Scotia Capital maintained it with “Focus Stock” rating and $24 target in Thursday, November 23 report. Scotia Capital maintained it with “Outperform” rating and $14.50 target in Friday, July 8 report. The firm has “Outperform” rating given on Tuesday, January 10 by Scotia Capital. On Wednesday, March 29 the stock rating was maintained by Scotia Capital with “Focus Stock”.

Eagle Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing and commercializing injectable products primarily in the critical care and oncology areas in the United States. The company has market cap of $803.14 million. The firm offers argatroban for heparin-induced thrombocytopenia; Ryanodex for malignant hyperthermia; non-alcohol docetaxel injection, a chemotherapeutic agent for breast, non-small cell lung, prostate, head, and neck cancers/gastric adenocarcinoma; and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin's lymphoma. It has a 16.53 P/E ratio. The Company’s product candidates includes include EP-4104, a dantrolene sodium for exertional heat stroke; EGL-4104-C-1702, dantrolene sodium for drug induced hyperthermia; EP-5101 for lung cancer and mesothelioma; and EGL-5385-C-1701 (fulvestrant) for breast cancer.

Among 4 analysts covering Eagle Pharma (NASDAQ:EGRX), 3 have Buy rating, 1 Sell and 0 Hold. Therefore 75% are positive. Eagle Pharma had 24 analyst reports since July 29, 2015 according to SRatingsIntel. As per Monday, June 20, the company rating was downgraded by Mizuho. The company was maintained on Thursday, November 3 by RBC Capital Markets. Mizuho maintained Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) rating on Thursday, October 26. Mizuho has “Sell” rating and $37.0 target. The stock of Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) earned “Buy” rating by Mizuho on Friday, February 26. The rating was maintained by Mizuho with “Sell” on Wednesday, March 21. The firm has “Buy” rating given on Friday, July 14 by RBC Capital Markets. Mizuho maintained the stock with “Buy” rating in Wednesday, October 26 report. As per Monday, December 18, the company rating was maintained by Mizuho. The stock of Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) has “Outperform” rating given on Tuesday, May 10 by RBC Capital Markets. The firm has “Underperform” rating given on Monday, January 9 by Mizuho.

Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: